EUVIMEDEUVIMED entdecken
Crossref

Single‐time‐point tumor dosimetry using population‐based model selection and nonlinear mixed‐effects modeling in [ 177 Lu]Lu‐PSMA‐617 therapy

Deni Hardiansyah, Elham Yousefzadeh-Nowshahr, Indra Budiansah, Ursula Nemer, Ade Riana, Felix Kind, Ambros J Beer, Philipp T Meyer, Gerhard Glatting, Michael Mix

Medical Physics · 2025

DOI: 10.1002/mp.70000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Physics, 2025. Verfasst von Deni Hardiansyah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia. Hauptthemen laut MEDLINE: Radiometry, Lutetium, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: PUTI Q1 grant 2024 from Universitas Indonesia, DAAD (German Academic Exchange Service), Förderkennzeichen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular radiotherapy with [ 177 Lu]Lu‐PSMA‐617 is an effective treatment for metastatic castration‐resistant prostate cancer. Accurate dosimetry is essential for maximizing therapeutic efficacy while minimizing toxicity. However, standard dosimetry requires multiple imaging sessions, posing logistical challenges. Single‐time‐point (STP) dosimetry offers a practical alternative but remains challenging for tumor kinetics due to high inter‐patient variability. Nonlinear mixed‐effects (NLME) modeling, combined with population‐based model selection (PBMS), has demonstrated potential for improving STP dosimetry accuracy.

Purpose

The purpose of this study was to evaluate the accuracy of STP tumor dosimetry using SPECT/CT data, PBMS, and an NLME model in a large population with diverse biokinetic measurements for [ 177 Lu]Lu‐PSMA‐617 therapy.

Methods

Biokinetic data for [ 177 Lu]Lu‐PSMA‐617 in tumors were obtained from forty‐nine patients with metastatic castration‐resistant prostate cancer using SPECT/CT at time points (1.80 ± 0.80), (18.67 ± 0.90), (42.63 ± 1.03), (66.27 ± 0.96), and (159.02 ± 23.35) h after injection. Ten different functions, derived from various parameterizations of two‐ to four‐exponential functions, were fitted to the data using the NLME framework. Each function's parameters were defined as a combination of fixed and random effects. A PBMS approach was employed, using goodness‐of‐fit tests and Akaike weights to identify the function best supported by the data. The selected function from the NLME fitting of all time points with the leave‐one‐out method was used to calculate the reference time‐integrated activities per volume (TIAVs). The parameters from STP fitting were used to calculate the STP TIAVs. Additionally, STP dosimetry was performed using the Hänscheid method to calculate the TIAVs. Relative deviations (RDs) and root‐mean‐square errors (RMSEs) were used to analyse the accuracy of the calculated STP TIAVs and Hänscheid method TIAVs compared with the reference TIAVs.

Results

The function was selected as the fit function most supported by the data with an Akaike weight of 93%. For STP dosimetry, a single SPECT/CT measurement at time point 4 (66.3 ± 0.9 h) after injection showed a relatively low mean RD of 0.5% ± 11.0% and median RD of ‐0.6%. The RMSEs for the STP TIAVs RDs for time points 1–5 were 53%, 29%, 17%, 11%, and 38%, respectively. The STP tumor dosimetry using the PBMS NLME method outperformed the Hänscheid method for all investigated time points.

Conclusion

Our findings demonstrate that a single SPECT/CT measurement at 3 days after injection may be used to estimate tumor TIAVs in [ 177 Lu]Lu‐PSMA‐617 therapy using the NLME method and PBMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiometryLutetiumHeterocyclic Compounds, 1-RingDipeptidesNonlinear DynamicsProstatic Neoplasms, Castration-ResistantHumansMaleTime FactorsRadioisotopesAgedSingle Photon Emission Computed Tomography Computed TomographyProstate-Specific Antigen

Stichwörter der Autor:innen

Akaike weightNLME modelingPSMASTP dosimetrymodel selectiontumor dosimetry

Substanzen

LutetiumHeterocyclic Compounds, 1-RingDipeptidesLutetium-177PSMA-617RadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, Indonesia.
  • Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany.
  • Department of Nuclear Medicine, Ulm University, Ulm, Germany.
  • Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Radiation Protection and Compliance Testing Laboratory, Medical Devices and Facilities Safety Centre, Jakarta, Indonesia.
  • Department of Medical Imaging and Clinical Oncology, Nuclear Medicine Division, Faculty of Medicine and Health Science, Stellenbosch University, Stellenbosch, South Africa.

Förderung

  • PUTI Q1 grant 2024 from Universitas Indonesia
  • DAAD (German Academic Exchange Service), Förderkennzeichen

Zitieren

APA

Hardiansyah, D., Yousefzadeh-Nowshahr, E., Budiansah, I., Nemer, U., Riana, A., Kind, F., Beer, A. J., Meyer, P. T., Glatting, G., & Mix, M. (2025). Single‐time‐point tumor dosimetry using population‐based model selection and nonlinear mixed‐effects modeling in [ 177 Lu]Lu‐PSMA‐617 therapy. Medical Physics. https://doi.org/10.1002/mp.70000

Vancouver

Hardiansyah D, Yousefzadeh-Nowshahr E, Budiansah I, Nemer U, Riana A, Kind F, et al. Single‐time‐point tumor dosimetry using population‐based model selection and nonlinear mixed‐effects modeling in [ 177 Lu]Lu‐PSMA‐617 therapy. Medical Physics. 2025. doi:10.1002/mp.70000

BibTeX
@article{Hardiansyah2025,
  author = {Hardiansyah, Deni and Yousefzadeh-Nowshahr, Elham and Budiansah, Indra and Nemer, Ursula and Riana, Ade and Kind, Felix and Beer, Ambros J and Meyer, Philipp T and Glatting, Gerhard and Mix, Michael},
  title = {Single‐time‐point tumor dosimetry using population‐based model selection and nonlinear mixed‐effects modeling in [ 177 Lu]Lu‐PSMA‐617 therapy},
  journal = {Medical Physics},
  year = {2025},
  doi = {10.1002/mp.70000}
}
Kostenlos starten →